key: cord-0846009-dbrw6fn3
authors: Ejemel, Monir; Li, Qi; Hou, Shurong; Schiller, Zachary A.; Wallace, Aaron L.; Amcheslavsky, Alla; Yilmaz, Nese Kurt; Toomey, Jacqueline R.; Schneider, Ryan; Close, Brianna J.; Chen, Da-Yuan; Conway, Hasahn L.; Mohsan, Saeed; Cavacini, Lisa A.; Klempner, Mark S.; Schiffer, Celia A.; Wang, Yang
title: IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity
date: 2020-05-15
journal: bioRxiv
DOI: 10.1101/2020.05.15.096719
sha: 4780ad1e1310e82d7f7caf4b2124fa8fc7a62163
doc_id: 846009
cord_uid: dbrw6fn3

COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

Interventions for the prevention or treatment of COVID-19 are crucial for the ongoing outbreak. 39 Pre-or post-exposure immunotherapies with neutralizing antibodies, would be of great use by 40 providing immediate mucosal immunity against SARS-CoV-2. Although concerns, as occurred 41 with SARS-CoV 5,6 , that vaccines may cause disease enhancement will need to be addressed. 42 The feasibility of human monoclonal antibodies (MAbs) as immunoprophylaxis or therapy 43 against coronaviruses including SARS-CoV 7-10 and MERS-CoV 11 has been demonstrated. These In the current study we describe the discovery of a cross-neutralizing human IgA monoclonal 68 antibody, MAb362 IgA. This IgA antibody binds to SARS-CoV-2 RBD with high affinity 69 directly competing at the hACE2 binding interface by blocking interactions with the receptor. 75 We have previously developed and characterized a panel of human MAbs that targets the RBD 76 of the SARS-CoV S glycoprotein, isolated from transgenic mice expressing human 77 immunoglobulin genes 9,10 . These 36 hybridomas were recently screened against the SARS-CoV-78 2 Spike protein for potential cross-bind activity. MAb362 was identified with cross-binding 79 activity against both the S1 subunit of the SARS-CoV S1-590 and SAR-CoV-2 S1-604 proteins 80 (Extended Data MAb362 IgG and IgA were assessed in ELISA binding assays against the receptor-binding 87 domain (RBD) of the S1 subunit for SARS-CoV S270-510 and SARS-CoV-2 S319-541 (Figure 1a ).

MAb362 IgA showed better binding activities, compared to its IgG counterpart against with 89 SARS-CoV-2 S319-541 (Figure 1b) . Assessment of the binding kinetics was consistent with the 90 ELISA binding trends, the binding affinity of IgA with RBD of SARS-CoV-2 is significantly 91 higher (0.3 nM) than that of IgG (13 nM) due to a much slower dissociation rate as an IgA (Koff 92 = 1.13x10 -3 ± 1.06x10 -4 ) compared to an IgG (Koff = 7.75x10 -5 ± 5.46x10 -5 ) (Figure 1c- To define the antibody-binding epitope, known co-crystal and cryo-EM complexes from SARS-

CoV and MERS spike protein in complex with neutralizing antibodies were evaluated for their 99 potential to competitively block hACE2 binding, based on the structural interface of hACE2- Complementing the mutational analysis, to correlate the epitope binding with functionality,

MAb362 IgG and IgA were tested in a receptor-blocking assay with hACE2 expressing Vero E6 

To evaluate the neutralization potency of cross-reactive MAb362, we performed a pseudovirus IgG weakly neutralized SARS-CoV-2 pseudovirus despite its activities to block receptor binding.

Interestingly, isotype switch to MAb362 IgA1 resulted in significantly enhanced neutralization 159 potency, compared to its IgG subclass variant (Figure 4b) . Monomeric MAb362 IgA1 was also 160 co-expressed with J chain to produce dimeric IgA, which further improved neutralization 161 (Figure 4b) . This is consistent with our prior study showing isotype switch to IgA1 lead to 162 improved antibody neutralization of HIV infection 25 Our data extends this observation to 163 coronavirus, suggesting that IgA may play an important role in SARS-CoV-2 neutralization. CoV-2 (S319-541) were conducted using bio-layer interferometry and demonstrate nano and sub-303 nanomolar affinities. Data is plotted as the average ± SD from two independent experiments. Dilutions of purified MAbs were tested in ELISA for reactivity against recombinant S protein.

Briefly, 96-well plates were coated with S proteins followed by incubation overnight at 4°C. 

RBD expression vectors and RBD proteins were purified as described above. Mutant RBD were 438 confirmed intact expression on proteins gels, and the same amount of proteins were coated on the 439 plate for ELISA assays

PALL/ForteBio) was used to determine the 444 affinity of MAb362 IgG and IgA1 to the RBD of SARS-CoV and SARS-CoV-2 S protein. MAbs 445 were added to 96 wells plates at 1000 nM and titrated 1:2 to 62 nM using PBS. RBD from 446 SARS-CoV and SARS-CoV-2 were biotinylated

SA) Biosensors (ForteBio) for 120 seconds at 1600nM concentration. After a 448 baseline step, MAb362-RBD binding rate was determined when the biosensors with immobilized 449 RBD were exposed to MAb362 IgG or IgA1 at different concentrations for 120 seconds

Following association, the MAb362-RBD complex was exposed to PBS and the rate of the 451

MAb362 dissociation from RBD was measured. Each assay was performed in triplicate

Statistical calculations were performed using Prism version 7.03 (GraphPad Software